Document is current
Any future updates will be listed below
-
Authors
Munitz, Ariel https://orcid.org/0000-0003-1626-3019
Edry-Botzer, L.
Itan, M.
Tur-Kaspa, R.
Dicker, D.
Marcoviciu, D.
Goren, M. G.
Mor, M.
Lev, S.
Gottesman, T.
Muhsen, K.
Cohen, D.
Stein, M.
Qimron, U.
Freund, N. T.
Wine, Y.
Gerlic, Motti https://orcid.org/0000-0001-9518-1833
-
Funding
Funding for this research was provided by:
Alpha-1 Foundation (615533)
United States-Israel Binational Science Foundation
Israel Science Foundation
Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University
development grant from Biological Industries, Beit Haemek, Israel
Israel Cancer Research Fund
H2020 European Research Council (818878)
Israeli Innovation Authority
Milner Foundation
- License Information
-
More Information
Article History
Received: 30 August 2020
Accepted: 13 January 2021
First Online: 10 February 2021
Competing interests
: MA and GM filed a patent application regarding antibodies that were presented in this study. The authors have no additional financial interests.
